Developments in the Treatment of
Paroxysmal Nocturnal Hemoglobinuria

Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Two Dates!
July 25th 12:00 pm - 12:30 pm ET
July 28th 3:00 pm - 3:30 pm ET

Live Virtual Meeting


Robert Sidonio, Jr., MD Angela C. Weyand, MD
Elizabeth Griffiths, MD
Associate Professor
State University of New York
Buffalo, New York
Ilene C. Weitz, MD
Professor of Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California

Program Overview
The faculty will highlight the latest updates on clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and provide their practical clinical insights to enhance the implementation of these trials into practice. You will have the ability to discuss new agents with two leading experts, explore how patient management is approached today, and what treatment may look like in the near future.


C5 Inhibitors
• Eculizumab
• Ravulizumab
• Pozelimab
• Crovalimab
Proximal Complement Inhibitors
• C3b binding
– Pegcetacoplan
– Pegcetacoplan
• Factor B
– LNP023 (Novartis)
• Factor D
– Danicopan (ACH-4471)
• Combination treatments
– Combination of C3 and C5 inhibition, Factor D and C5 inhibition, or C5 inhibition using different modalities. The combination of a licensed C5 inhibitor (eculizumab or ravulizumab), with an ‘add on’ proximal complement inhibitor
Conclusion and Discussion
Interactive Question and Answer Session

Target Audience
This program is intended for hematology/oncology physicians, nurse practitioners, pharmacists and other clinicians who provide care for patients with paroxysmal nocturnal hemoglobinuria.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Describe the role of complement in the pathophysiology of PNH
  • Assess the efficacy of anti-complement treatment in patients with PNH
  • Summarize novel agents currently available in clinical practice and those emerging agents in clinical development


MediCom Worldwide, Inc. CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-007-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Dr. Elizabeth Griffiths has relevant financial relationships related to consulting from AbbVie Inc., Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, Inc., Novartis AG, PicnicHealth, Taiho Pharmaceutical Co., Ltd, and Takeda Oncology, as well as advisory activities from Alexion and PicnicHealth. She has received research grants from Alexion, Apellis, Astex, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, and Novartis.

Dr. Ilene Weitz has relevant financial relationships related to consulting from Alexion, Apellis, and BioCryst Pharmaceuticals, Inc. She is on the speakers’ bureau for Alexion.

All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

CME and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or [email protected].
Provided by
MediCom Worldwide, Inc. Supported by an educational grant from BioCryst US Sales Co., LLC.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.